"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 2 | 3 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 6 | 8 |
| 2012 | 6 | 6 | 12 |
| 2013 | 4 | 8 | 12 |
| 2014 | 7 | 10 | 17 |
| 2015 | 11 | 4 | 15 |
| 2016 | 11 | 13 | 24 |
| 2017 | 9 | 13 | 22 |
| 2018 | 16 | 10 | 26 |
| 2019 | 12 | 6 | 18 |
| 2020 | 19 | 16 | 35 |
| 2021 | 19 | 23 | 42 |
| 2022 | 5 | 40 | 45 |
| 2023 | 2 | 35 | 37 |
| 2024 | 14 | 12 | 26 |
| 2025 | 7 | 21 | 28 |
| 2026 | 9 | 6 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Peripheral human mAb therapy yields modulation of neuroinflammation and long-term functional recovery from lyssavirus infection. Emerg Microbes Infect. 2026 Dec; 15(1):2736987.
-
Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion. Nat Commun. 2026 08 26; 17(1).
-
A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody. EMBO Rep. 2026 08; 27(15):4583-4601.
-
Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. Pediatrics. 2026 Jun 01; 157(6).
-
Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses. EBioMedicine. 2026 May; 127:106269.
-
Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge. J Clin Invest. 2026 May 15; 136(10).
-
A Test-Negative Design for Immune Correlates Approximates a Traditional Exposure-Proximal Design but Requires Far Fewer Blood Samples. J Infect Dis. 2026 Mar 17; 233(3):e646-e650.
-
Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants. Nat Microbiol. 2026 Apr; 11(4):1113-1132.
-
Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study. Blood Adv. 2026 Mar 10; 10(5):1564-1575.
-
The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 02; 77:128358.